These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 20226548)

  • 21. Fondaparinux with UnfracTionated heparin dUring Revascularization in Acute coronary syndromes (FUTURA/OASIS 8): a randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes initially treated with fondaparinux.
    Steg PG; Mehta S; Jolly S; Xavier D; Rupprecht HJ; Lopez-Sendon JL; Chrolavicius S; Rao SV; Granger CB; Pogue J; Laing S; Yusuf S
    Am Heart J; 2010 Dec; 160(6):1029-34, 1034.e1. PubMed ID: 21146654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Argatroban: a direct thrombin inhibitor with reliable and predictable anticoagulant actions.
    Escolar G; Bozzo J; Maragall S
    Drugs Today (Barc); 2006 Apr; 42(4):223-36. PubMed ID: 16703119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects.
    Swan SK; St Peter JV; Lambrecht LJ; Hursting MJ
    Pharmacotherapy; 2000 Jul; 20(7):756-70. PubMed ID: 10907966
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction.
    Levine RL; Hursting MJ; McCollum D
    Chest; 2006 May; 129(5):1167-75. PubMed ID: 16685006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized, open-label pilot study comparing desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis: PREVENT-HIT Study.
    Boyce SW; Bandyk DF; Bartholomew JR; Frame JN; Rice L
    Am J Ther; 2011 Jan; 18(1):14-22. PubMed ID: 21079512
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of argatroban for extracorporeal life support in patients with nonheparin-induced thrombocytopenia: Analysis of 10 consecutive patients.
    Kim YS; Lee H; Yang JH; Sung K; Suh GY; Chung CR; Yang JH; Cho YH
    Medicine (Baltimore); 2018 Nov; 97(47):e13235. PubMed ID: 30461625
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Argatroban: a review of its use in the management of heparin-induced thrombocytopenia.
    Dhillon S
    Am J Cardiovasc Drugs; 2009; 9(4):261-82. PubMed ID: 19655821
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of bolus only with bolus plus infusion of bivalirudin in patients undergoing elective percutaneous coronary intervention: a retrospective observational study.
    Sheikh-Taha M; Ghosn S
    J Pharm Pract; 2012 Oct; 25(5):537-40. PubMed ID: 22572222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic evaluation of argatroban for the treatment of acute coronary syndrome.
    Cruz-González I; López-Jiménez R; Perez-Rivera A; Yan BP
    Expert Opin Drug Metab Toxicol; 2012 Nov; 8(11):1483-93. PubMed ID: 22970706
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Argatroban in the management of heparin-induced thrombocytopenia.
    Babuin L; Pengo V
    Vasc Health Risk Manag; 2010 Sep; 6():813-9. PubMed ID: 20859550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of a prolonged bivalirudin infusion after urgent and complex percutaneous coronary interventions: a descriptive study.
    Cortese B; Micheli A; Picchi A; Bandinelli L; Brizi MG; Severi S; Limbruno U
    Coron Artery Dis; 2009 Aug; 20(5):348-53. PubMed ID: 19543084
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial.
    Mehta SR; Steg PG; Granger CB; Bassand JP; Faxon DP; Weitz JI; Afzal R; Rush B; Peters RJ; Natarajan MK; Velianou JL; Goodhart DM; Labinaz M; Tanguay JF; Fox KA; Yusuf S;
    Circulation; 2005 Mar; 111(11):1390-7. PubMed ID: 15781750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Argatroban as a substitute of heparin during cardiopulmonary bypass: a safe alternative?
    Follis F; Filippone G; Montalbano G; Floriano M; Lobianco E; D'Ancona G; Follis M
    Interact Cardiovasc Thorac Surg; 2010 Apr; 10(4):592-6. PubMed ID: 20061338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial.
    Montalescot G; Gallo R; White HD; Cohen M; Steg PG; Aylward PE; Bode C; Chiariello M; King SB; Harrington RA; Desmet WJ; Macaya C; Steinhubl SR;
    JACC Cardiovasc Interv; 2009 Nov; 2(11):1083-91. PubMed ID: 19926048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombocytopenia.
    Hursting MJ; Soffer J
    Drug Saf; 2009; 32(3):203-18. PubMed ID: 19338378
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between the intensity of heparin anticoagulation and clinical outcomes in patients receiving glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction.
    Rozenman Y; Mehran R; Witzenbichler B; Dangas G; Desaga M; Kochman J; Nilsen DW; Finkelstein A; Mosseri M; Stone GW
    Catheter Cardiovasc Interv; 2013 Jan; 81(1):E9-14. PubMed ID: 22511592
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.
    Brener SJ; Moliterno DJ; Lincoff AM; Steinhubl SR; Wolski KE; Topol EJ
    Circulation; 2004 Aug; 110(8):994-8. PubMed ID: 15302778
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.
    Lewis BE; Wallis DE; Berkowitz SD; Matthai WH; Fareed J; Walenga JM; Bartholomew J; Sham R; Lerner RG; Zeigler ZR; Rustagi PK; Jang IK; Rifkin SD; Moran J; Hursting MJ; Kelton JG;
    Circulation; 2001 Apr; 103(14):1838-43. PubMed ID: 11294800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of a new heparin agent in percutaneous coronary intervention: results of the phase 2 evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) Trial.
    Rao SV; Melloni C; Myles-Dimauro S; Broderick S; Kosinski AS; Kleiman NS; Dzavík V; Tanguay JF; Chandna H; Gammon R; Rivera E; Alexander JH; Fier I; Roach J; Becker RC;
    Circulation; 2010 Apr; 121(15):1713-21. PubMed ID: 20368520
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of bivalirudin and unfractionated heparin plus protamine in patients with coronary heart disease undergoing percutaneous coronary intervention (from the Antithrombotic Regimens aNd Outcome [ARNO] trial).
    Parodi G; Migliorini A; Valenti R; Bellandi B; Signorini U; Moschi G; Buonamici P; Cerisano G; Antoniucci D
    Am J Cardiol; 2010 Apr; 105(8):1053-9. PubMed ID: 20381652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.